Eculizumab has been marketed for the orphan disease paroxysmal nocturnal hemoglobinuria (PNH) preventing the intravascular lysis of RBC that lacks the membrane bound complement regulators CD55 and CD59 (47). The gene discussed is CD59; the disease is paroxysmal nocturnal hemoglobinuria.